New strategy for the identification of squamous carcinoma antigens that induce therapeutic immune responses in tumor-bearing mice

Cancer Gene Therapy

Volumn 14, Issue 4, 2007, Pages 389-398

  O Sullivan, I ^a   Chopra, A ^a   Kim, T S ^b   Magnuson, S ^c   Falduto, M T ^c   Huang, J ^a   Cohen, E P ^a,d  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Korea University   (South Korea)

^c GenUs BioSystems Inc   (United States)

^d Department of Microbiology and Immunology ^*  (United States)

Author keywords

Cyp2e1; DNA based vaccine; Immunotherapy; Squamous cell carcinoma

Indexed keywords

CANCER VACCINE; CYTOCHROME P450 2E1; DNA FRAGMENT; GENOMIC DNA; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER SURVIVAL; CARCINOMA CELL; CELL DIVISION; CELL POPULATION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SYNTHESIS; FEMALE; FIBROBLAST; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GENOME; GENOMIC FRAGMENT; IMMUNE RESPONSE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; SQUAMOUS CELL CARCINOMA;

MUS;

EID: 33947238491     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701023     Document Type: Article

References (49)

1. American Cancer Society: Cancer Facts and Figures 2006.
2. Herold-Mende C, Karcher J, Dyckhoff G, Schirrmacher V. Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine. Adv Otorhinolaryngol 2005; 62: 173-183.
3. Hoffmann TK, Bier H, Donnenberg AD, Whiteside TL, De Leo AB. p53 as an immunotherapeutic target in head and neck cancer. Adv Otorhinolaryngol 2005; 62: 151-160.
4. Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES et al. Immunity to oncogenic proteins. Immunol Rev 1995; 145: 33-59.
5. Disis ML, Cheever MA. Oncogenic proteins as tumor antigens. Curr Opn Immunol 1996; 8: 637-642.
6. Ferris RL. Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed? ORL J Otorhinolaryngol Relat Spec 2004; 66: 332-640.
7. Yoshitake Y, Nakatsura T, Monji M. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res 2004; 10: 6437-6448.
8. Russo G, Zegar C, Giordano A. Advantages and limitations of microarray technology in human cancer. Oncogene 2003; 22: 6497-6507.
9. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topolian SL et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-327.
10. Jaeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo, implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996; 66: 162-169.
11. Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M et al. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 2005; 93: 749-756.
12. Steitz J, Britten CM, Wolfel T, Tuting T. Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunol Immunother 2006; 55: 246-253.
13. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 2005; 28: 496-504.
14. Hus I, Rolinski J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Greiner J et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 1621-1627.
15. Hayashi T, Nakao K, Nagayama Y, Saitoh O, Ichikawa T, Ishikawa H et al. Vaccination with dendritic cells pulsed with apoptotic cells elicits effective antitumor immunity in murine hepatoma models. Int J Oncol 2005; 26: 1313-1319.
16. Cuadros C, Dominguez AL, Lollini PL, Croft M, Mittler RS, Borgstrom P et al. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int J Cancer 2005; 116: 934-943.
17. Dalgleish AG, Whelan MA. Cancer vaccines as a therapeutic modality: the long trek. Cancer Immunol Immunother 2006; 55: 1025-1032.
18. Boon T, Cerrottini JC, Van den Eynde B, van er Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12: 337-365.
19. Xu Y, Sette A, Sidney J, Gendler SJ, Franco A. Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention. Immunol Cell Biol 2005; 83: 440-448.
20. Mukherjee P, Tinder TL, Basu GD, Pathangey LB, Chen L, Gendler SJ. Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model. Breast Dis 2004; 20: 53-63.
21. Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol 2006; 28: 1089-1098.
22. Figueiredo DL, Mamede RC, Proto-Siqueira R, Neder L, Silva Jr WA, Zago MA. Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck 2006; 28: 614-619.
23. Kikuchi M, Nakao M, Inoue Y, Matsunaga K, Shichijo S, Yamana H et al. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer 1999; 81: 459-466.
24. Badoual C, Hans S, Rodriguez J et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006; 12: 465-472.
25. Shin KH, Kang MK, Kim RH, Kameta A, Baluda MA, Park NH. Abnormal DNA end-joining activity in human head and neck cancer. Int J Mol Med 2006; 17: 917-924.
26. Pecina-Slaus N, Kljaic M, Nikuseva-Martic T. Loss of heterozygosity of APC and CDH1 genes in laryngeal squamous cell carcinoma. Pathol Res Pract 2005; 201: 557-563.
27. Wang X, Fan M, Chen X, Wang S, Alsharif MJ, Wang L et al. Intratumor genomic heterogeneity correlates with histological grade of advanced oral squamous cell carcinoma. Oral Oncol 2006; 42: 740-744.
28. Bavoux C, Leopoldino AM, Bergoglio V, O-Wang J, Ogi T, Bieth A et al. Up-regulation of the error-prone DNA polymerase {kappa} promotes pleiotropic genetic alterations and tumorigenesis. Cancer Res 2005; 65: 325-330.
29. Chopra A, Kim TS, O-Sullivan I, Martinez D, Cohen EP. Treatment of squamous carcinoma in mice with a vaccine enriched for cells that induce immunity to squamous carcinoma-A new vaccination strategy. Int J Cancer 2006; 119: 339-348.
30. Kim TS, Cohen EP. Immunity to breast cancer in mice immunized with fibroblasts transfected with a cDNA expression library derived from small numbers of breast cancer cells. Cancer Gene Ther 2005; 12: 890-899.
31. Kaneko T, LePage GA, Shnitka TK. KLN205-a murine lung carcinoma cell line. In vitro 1980; 16: 884-892.
32. de Zoeten BF, Carr-Brendel V, Cohen EP. Resistance to melanoma in mice immunized with semi-allogeneic fibroblasts transfected with genomic DNA from melanoma cells. J Immunol 1998; 160: 2915-2922.
33. de Zoeten B, Carr-Brendel V, Markovic D, Taylor-Papadimitriou J, Cohen EP. Immunity to breast cancer in mice immunized with semi-allogeneic fibroblasts transfected with DNA from breast cancer cells. J Immunol 1999; 162: 6934-6941.
34. Wigler M, Pellicer A, Silverstein S, Axel R, Urlaub G, Chasin L. DNA-mediated transfer of the adenine phosphoribosyl transferase locus into mammalian cells. Proc Natl Acad Sci USA 1979; 76: 1373-1376.
35. Gilboa E. The makings of a tumor rejection antigen. Immunity 1999; 11: 263-270.
36. Kuss I, Schaefer C, Godfrey TE, Ferris RL, Harris JM, Gooding W et al. Recent thymic emigrants and subsets of naive and memory T cells in the circulation of patients with head and neck cancer. Clin Immunol 2005; 16: 27-36.
37. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S et al. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 2005; 11: 2552-2560.
38. Whiteside TL. Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005; 24: 95-105.
39. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006; 16: 3-15.
40. Barraclough R, Chen HJ, Davies BR, Davies MP, Ke Y, Lloyd BH et al. Use of DNA transfer in the induction of metastasis in experimental mammary systems. Biochem Soc Symp 1998; 63: 273-294.
41. Kavathas P, Herzenberg LA. Stable transformation of mouse LM cells (a transformed fibroblast cell line) for human membrane T-cell differentiation antigens, HLA and B2 microglobulin: selection by fluorescence-activated cell sorting. Proc Natl Acad Sci USA 1983; 80: 524-528.
42. Shih C, Shilo B-Z, Goldfarb MP, Dannenberg A, Weinberg RA. Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc Natl Acad Sci USA 1979; 76: 5714-5718.
43. Shih C, Weinberg RA. Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 1982; 29: 161-169.
44. Fanceschi S, Talamini R, Barra S, Baron AE, Negri E, Bidoli E. Smoking and drinking in relation to cancer of the oral cavity, pharynx, larynx and esophagus in northern Italy. Cancer Res 1990; 50: 6502-6507.
45. Yamazaki H, Inui Y, Yun CH, Guengerich FP, Shimada T. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992; 13: 1789-1794.
46. Maecker B, von Bergwelt-Baildon MS, Anderson KS, onderheide RH, Anderson KC, Nadler LM et al. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin Exp Immunol 2005; 141: 558-562.
47. Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005; 11: 4430-4436.
48. Maecker B, von Bergwelt-Baildon MS, Sherr DH, Nadler LM, Schultze JL. Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int J Cancer 2005; 115: 333-336.
49. Kan T, Yamasaki S, Kondo K, Teratani N, Kawabe A, Kaganoi J et al. A new specific gene expression in squamous cell carcinoma of the esophagus detected using representational difference analysis and cDNA microarray. Oncology 2006; 70: 25-33.